Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized vs Standardized PN in Preterm Infants >1250g
NCT03693287Phase 4Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Lipid-based Nanoparticles, Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Numeta G13 in Prematurity (PTB) (2 arms), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Weight Change. Status: unknown.
02
Drugs
Numeta G13
03
Conditions
Prematurity (PTB)
Beyond the preview
Go deeper on NCT03693287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693287.